Spondylarthritis (Spinal Arthritis)

01/01/2013 - "2 cases of HLA-B27-positive seronegative spondylarthritides in pediatric age treated with adalimumab."
04/19/2011 - "Spondylarthritis presenting with an allergic immediate systemic reaction to adalimumab in a woman: a case report."
07/01/2008 - "Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two."
04/19/2011 - "We report the case of a 61-year-old Caucasian woman who was treated with adalimumab for spondylarthritis and developed injection site reactions after the sixth dose. "
01/01/2010 - "Mycobacterium chelonae infection under adalimumab therapy for spondylarthritis."

01/01/2020 - "From observational studies to personalized treatment in spondylarthritis: focus on IL-17 inhibition."
01/01/2021 - "The spondylarthritides (SpA) are intimately linked to new bone formation and IL-17A and TNF pathways. "
05/01/2001 - "Chondrocytes from all types of arthritides were negative for IL-17 staining, but expressed IL-17R; the highest percentage of positive chondrocytes was found in seronegative spondylarthritis and the lowest in RA. "
04/01/2023 - "Therapeutic intervention to block IL-17A signaling has proven to be an effective treatment for numerous autoimmune diseases, including psoriasis, psoriatic arthritis, and axial spondylarthritis. "
10/01/2021 - "Ixekizumab: an IL-17A inhibitor for the treatment of axial Spondylarthritis."

04/01/2009 - "This study is the first to show that infliximab is effective for reducing clinical and imaging evidence of disease activity in patients with MRI-determined early axial spondylarthritis."
03/01/2010 - "[Protocol for inducing infliximab tolerance in a patient with psoriatic spondylarthritis]."
10/01/2007 - "The case of a young male is described, affected by Crohn disease with reactive Spondylarthritis essay with Infliximab to the dose of 3 mg/kgs. "
11/06/2020 - "Methods We conducted a cross-sectional multicentric study including patients with spondylarthritis (SpA) under antiTNF (infliximab [INF], etanercept [ETA] and adalimumab [ADL]) for at least 6 months. "
07/01/2009 - "We collected 69 cases of TB in patients treated for rheumatoid arthritis (n = 40), spondylarthritides (n = 18), inflammatory colitis (n = 9), psoriasis (n = 1) and Behçet's disease (n = 1) with infliximab (n = 36), adalimumab (n = 28), and etanercept (n = 5). "

01/01/2021 - "Background: Secukinumab has been shown effective for psoriatic arthritis (PsA) and axial spondylarthritis (AxSpA) in randomized trials. "
01/01/2022 - "The article presents the results of studies demonstrating the influence of interleukin-17 inhibitor secukinumab on the course of uveitis in spondylarthritis, shows the possibilities of treating uveitis in juvenile idiopathic arthritis with inhibitors of interleukin-6, co-stimulation of T-lymphocytes. "

03/09/2016 - "Non-steroidal anti-inflammatory drugs (NSAID) are the first line treatment for spondylarthritis. "
12/01/2023 - "[Dealing with NSAID in the treatment of axial spondylarthritis]."
02/01/2012 - "This study confirms the feasibility and simplicity of the ASAS-NSAID score and suggests that such a score be integrated in all studies in spondylarthritis either to check the quality of the observed data (i.e., intergroup baseline characteristics) or to evaluate the NSAID-sparing effect of other therapies."
02/01/2020 - "Drug treatment in patients with axial spondylarthritis (axSpA) aims to modify symptoms and complaints and currently includes the substance groups of nonsteroidal anti-inflammatory drugs (NSAID) and biologicals (disease-modifying antirheumatic drugs, bDMARDS). "

03/01/2021 - "The aim of this study was to demonstrate the successful use of tofacitinib in SSc and axial spondylarthritis (axSpa), as a novel therapeutic agent; however, further studies are needed to elucidate the role of JAK inhibition in the treatment of both conditions. "

07/01/2005 - "[Current evaluation of efficacy of radon baths of various concentrations during rehabilitation of patients with seronegative spondylarthritis]."
07/01/2005 - "141 patients with seronegative spondylarthritis including ankylosing spondylarthritis (n = 90), reactive arthritis and Reiter's disease (n = 51) took water radon baths (concentration 1.5, 3.0 and 4.5 kB/l). "

09/01/2023 - "Therapeutic efficacy of Janus kinase inhibitors is now well established in the treatment of array of autoimmune and inflammatory disease: spondylarthritis with a special focus on psoriatic arthritis (PsA) and its dermatologic manifestations (psoriasis) and ankylosing spondylitis (AS), atopic dermatitis (AD), alopecia areata (AA), rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). "

10/10/2023 - "Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study."
10/01/2011 - "Increasing the etanercept dose to 100 mg/week improves efficacy in cutaneous psoriasis, a clinical manifestation related to the spondylarthritis family, while maintaining its safety profile. "
09/01/2007 - "We report the development of thymic atypical carcinoid tumor 9 months after the initiation of etanercept therapy in a patient having refractory spondylarthritis. "
10/10/2023 - "To characterize disease activity trajectories and compare long-term drug retention between rheumatoid (RA) and spondylarthritis (SpA) patients initiating tumor necrosis factor inhibitor (TNFi) treatment (etanercept). "
02/01/2013 - "The second was a 42-year-old man who received adalimumab and then etanercept for a peripheral spondylarthritis. "

08/01/2021 - "Nevertheless, we present a case of an AAV in a 53-year-old female with enteropathic spondylarthritis previously treated with tumor necrosis factor α inhibitors (TNFi). "
10/01/2012 - "Inhibition of inflammation and destruction, but not of osteoproliferation, in patients with spondylarthritis (SpA) treated with anti-tumor necrosis factor raises the question of how these three processes are interrelated. "
06/01/2003 - "There is increasing evidence that tumor necrosis factor alpha (TNFalpha) is centrally involved in the pathogenesis of ankylosing spondylitis (AS) and other spondylarthritides. "
02/01/2007 - "To study the relationship between inflammation and remodeling by inhibiting tumor necrosis factor alpha (TNFalpha) in male DBA/1 mice with spontaneous arthritis, a model of spondylarthritis (SpA). "
10/01/2010 - "To introduce a novel, simple, utility-based outcome measure, the number needed per quality-adjusted life year (QALY) gained (NNQ), and to apply it in clinical practice in anti-tumor necrosis factor (anti-TNF)-treated patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondylarthritis (SpA). "

11/01/1957 - "[Efficacy of ultrasonic therapy in comparison with other physical therapeutic methods in painful complications of spondylarthritis]."

07/01/2005 - "The baths proved similarly effective in patients with seronegative spondylarthritis. "
07/01/2005 - "[Current evaluation of efficacy of radon baths of various concentrations during rehabilitation of patients with seronegative spondylarthritis]."
07/01/2005 - "141 patients with seronegative spondylarthritis including ankylosing spondylarthritis (n = 90), reactive arthritis and Reiter's disease (n = 51) took water radon baths (concentration 1.5, 3.0 and 4.5 kB/l). "

01/01/2020 - "Therapy of patients with spondylarthritis (SA) remains one of the most difficult problems of modern rheumatology. "
01/01/2014 - "[Ocular involvement in spondylarthritis--new mechanisms, new therapies]."
05/10/1999 - "5. (final): therapy of special manifestation forms of spondylarthritis]."
04/30/1999 - "4: therapy of spondylarthritis]."
06/30/1990 - "[Progress in therapy of spondylarthritis]."

11/06/2007 - "Our studies on invasive cane toads in Australia reveal severe spinal arthritis in approximately 10% of large adult toads, associated with the same factors (large body size, frequent movement, and relatively long legs) that have enabled toads to invade so rapidly across the Australian tropics."
09/27/2019 - "Spinal arthritis in invasive cane toads is linked to rate of dispersal as well as to latitude."
01/01/2018 - "Increased prevalence of spinal arthritis may occur in cane toad populations at the invasion front as a cost of increased invasiveness, but our knowledge of the ecological drivers of this condition is lacking. "
01/01/2018 - "Spinal arthritis in cane toads across the Australian landscape."
12/01/2017 - "Several parasites and pathogens of Australian taxa have host-shifted to cane toads in Australia; for example, invasion-front toads are susceptible to spinal arthritis caused by the soil bacterium, Ochrobactrum anthropi. "

03/09/2023 - "Axial spondylarthritis (axSpA) is an inflammatory rheumatic disease that causes pain, diminished quality of life, limitations in activities of daily living and ability to work, especially if insufficiently treated. "
11/06/2020 - "Methods We conducted a cross-sectional multicentric study including patients with spondylarthritis (SpA) under antiTNF (infliximab [INF], etanercept [ETA] and adalimumab [ADL]) for at least 6 months. "